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six months pre-index (“baseline period”); and age<65 for six months post-index 
(“study period”). Baseline characteristics and study period prescription  
drug initiations (requiring six-month washout) by PA status (Iowa PA policy 
begun 5/24/2010) were compared between the two cohorts in each state. Logistic 
models were used to calculate risk-adjusted study period drug initiation rates, 
controlling for baseline characteristics. RESULTS: Iowa patients had significantly 
(p<.05) higher rates of anxiety and lower baseline health care costs 2010 versus 
2009 (n=9,429 vs. n=8,443). Missouri patients were significantly younger, had 
higher rates of mental disorders, and higher baseline health care costs in 2010 
versus 2009 (n=19,541 vs. n=13,083). In Iowa, risk-adjusted initiations  
of antidepressants (2009-2010) without PA increased significantly (17.8% vs. 
19.4%); initiations decreased significantly for: duloxetine (2.0% vs.1.6%), other 
antidepressants with PA (4.2% vs. 1.2%), and atypical antipsychotics without  
PA (7.5% vs. 6.7%). In Missouri, initiations increased significantly (2009-2010)  
for antidepressants without PA (21.4% vs. 24.2%) and atypical antipsychotics 
without PA (10.0% vs. 10.8%); the duloxetine initiation rate was not significantly 
different (2.9% vs. 2.7%). CONCLUSIONS: The Iowa Medicaid PA for duloxetine 
reduced the rate of duloxetine initiations, and did not increase atypical 
antipsychotic use.  
 
PMH74  
IDENTIFYING SCHIZOPHRENIA PATIENTS AT HIGH-RISK FOR ANTIPSYCHOTIC 
NONADHERENCE USING THE ASSESSMENT FOR QUALITY IMPROVEMENT AND 
RISK EVALUATION TOOL  
Muser E1, Slabaugh SL2, Louder A2, Patel N3 
1Janssen Scientific Affairs, LLC, O'Fallon, MO, USA, 2Competitive Health Analytics, Inc., 
Louisville, KY, USA, 3Competitive Health Analytics, LLC, Louisville, KY, USA  
OBJECTIVES: Compare antipsychotic adherence and costs among patients with 
schizophrenia identified as “high-risk” for future antipsychotic nonadherence by 
the Assessment for Quality Improvement and Risk Evaluation (QI-RE) tool to 
controls not identified as high-risk. QI-RE is a software tool developed by Janssen 
Scientific Affairs, LLC and Boston Health Economics, Inc. that applies adapted 
published regression equations to pharmacy and medical claims data to assess 
schizophrenic patients’ risk for future antipsychotic nonadherence. METHODS: 
Retrospective analysis using pharmacy, medical, and eligibility data from 
Humana Medicare Advantage patients diagnosed with schizophrenia (ICD-9-CM 
295.xx) having continuous enrollment from 1/1/2010-12/31/2011. QI-RE and data 
from 2010 were used to identify patients in the highest-risk quartile for future 
antipsychotic nonadherence (high-risk cohort). The remaining patients in the 
study population (lower-risk) acted as the control cohort. Antipsychotic 
adherence (proportion of days covered [PDC]), persistence (14 day gap allowance) 
and health care costs during 2011 were compared across both cohorts. Student’s 
t-tests and chi-square tests were used for continuous and categorical variables, 
respectively. RESULTS: Relative to the control cohort (n=3,867), the high-risk 
cohort (n=1,139) was younger (mean age 54.6 vs. 55.4 years, p<0.041) and had 
more African Americans (26.0% vs. 17.8%, p<0.001). During follow-up, mean PDC 
was 0.48 versus 0.81 (p<0.001); persistence was 119.3 versus 144.3 days (p<0.001); 
antipsychotic pharmacy costs were $1,950 versus $3,933 (p<0.001); and, 
psychiatric-related medical costs were $4,938 versus $4,452 (p=0.192) for high-
risk and control cohorts, respectively. CONCLUSIONS: Patients identified as 
high-risk for antipsychotic nonadherence by QI-RE had poorer adherence, 
shorter persistency, and lower antipsychotic pharmacy costs during the follow-
up period relative to controls. These results support the potential utility of QI-RE 
for quality improvement initiatives related to antipsychotic adherence in 
patients with schizophrenia.  
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HOSPITALIZATION USING THE ASSESSMENT FOR QUALITY IMPROVEMENT 
AND RISK EVALUATION TOOL  
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OBJECTIVES: Examine hospitalization rates and costs for cohorts of patients with 
schizophrenia identified as ‘high-risk’ by the Assessment for Quality Improvement 
and Risk Evaluation (QI-RE) tool compared to cohorts not designated as ‘high-risk’. 
QI-RE is a software tool developed by Janssen Scientific Affairs, LLC and Boston 
Health Economics, Inc. that applies adapted published regression equations to 
pharmacy and medical claims to assess patients’ risk for future hospitalizations. 
METHODS: Retrospective analysis using pharmacy, medical, and eligibility claims 
data from Humana Medicare Advantage patients diagnosed with schizophrenia 
(ICD-9-CM 295.xx) having continuous enrollment from 1/1/2010-12/31/2011. QI-RE 
and data from 2010 were used to identify cohorts of patients in the highest-risk 
quartiles for future All-Cause (ACH) and Psychiatric-Related (PRH) hospitalization. 
For each hospitalization outcome, separate control cohorts were constructed with 
patients from the three lower-risk quartiles. Hospitalizations and costs during 1-
year follow-up (2011) were compared between high-risk and control cohorts. 
RESULTS: High-risk cohorts had a higher proportion of females (58.0% vs. 48.6% in 
ACH, p<.0001; 57.6% vs. 48.7% in PRH, p<.0001) and Caucasians (77.6% vs. 72.4% in 
ACH, p=.0042; 77.5% vs. 72.4% in PRH, p=.0048) relative to respective controls. During 
follow-up, the proportion with ≥1 hospitalization (56.5% vs. 26.0% in ACH, p<.0001; 
49.7% vs. 21.7% in PRH, p<.0001), mean number of hospitalizations (2.7 vs. 1.0 in 
ACH, p<.0001; 1.7 vs. 0.6 in PRH, p<.0001), and mean total health care costs ($23,203 
vs. $12,841 in ACH, p<.0001; $23,213 vs. $12,835 in PRH, p<.0001) were significantly 
higher for each QI-RE cohort relative to respective controls. CONCLUSIONS: Patients 
identified as high-risk by QI-RE experienced higher rates of hospitalizations and 
higher health care costs in the follow-up period relative to controls. These results 
support the potential utility of this population health tool for quality improvement 
and cost avoidance efforts in managing patients with schizophrenia.  
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CHARACTERISTICS OF ADULT MEDICAID BENEFICIARIES WITH 
SCHIZOPHRENIA TREATED WITH PALIPERIDONE PALMITATE AND PREDICTORS 
OF TREATMENT CONTINUITY  
Maiese BA1, Montejano LB1, Smith DM2, Clancy Z3, Pesa JA3 
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Bethesda, MD, USA, 
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OBJECTIVES: To describe characteristics of adult Medicaid beneficiaries with 
schizophrenia initiated with Paliperidone Palmitate (PP) and assess the 
relationships between such characteristics and treatment continuity. METHODS: 
Adult Medicaid enrollees with schizophrenia, 30+ days of treatment with PP, and 
6 months continuous enrollment prior to the first PP claim in 2009-2011 were 
identified in the MarketScan® Medicaid Multi-State Database. Exclusion criteria 
included dual eligible coverage, mental health carve-out, or a claim for Risperdal 
Consta at index. Characteristics were compared between three groups created 
based on days continuous with PP (Group A: ≥151, B: 91-150, C: 31-90). The first 
gap of 14+ days between the days covered by one claim and the date of the next 
claim was defined as the end of continuous therapy. Cox proportional hazards 
regression identified factors associated with PP treatment continuity over 6 
months. RESULTS: A total of 725 patients comprised the sample, of which 339 
(47%) were continuous with PP for ≥151 days. Overall, the average age for the 
sample was 39 years, 64% were male, 41% white. Pre-index characteristics for 
groups A vs C were significantly different with respect to the number of unique 
3-digit ICD-9 diagnosis codes (mean/SD: 8.8/7.3 vs 10.8/8.9; p=0.004), number of 
unique psychiatric diagnostic categories (2.8/2.0 vs 3.5/2.2; p<0.001), number of 
unique antipsychotic agents (1.6/1.0 vs 1.8/1.1; p=0.028), diagnosed bipolar 
disorder (17% vs 27%; p=0.003), diagnosed depression (20% vs 30%; p=0.006), 
diagnosed alcohol abuse (9% vs 15%; p=0.029) and percent of patients with any 
psychiatric hospitalization (30% vs 42%; p=0.002). Cox proportional hazards 
regression models (saturated & stepwise) did not identify any factors 
significantly associated with treatment continuity. CONCLUSIONS: Relative to 
patients continuous with PP therapy for longer than 151 days, patients with 31-
90 days of continuous therapy had a more complex profile of mental health 
comorbidites and pre-index resource utilization.  
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PIH1  
DRUG INTERACTIONS IN ELDERLY POPULATION IN PRIMARY HEALTH CARE  
Tomic N, Sabo A, Milijasevic B, Vukmirovic S 
Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro  
OBJECTIVES: Was to determine the percentage of drug interactions’ risk in 
elderly population receiving three or more drugs at the same time, also and 
degree of risk of severe, moderate and mild interactions. METHODS: This study 
was retrospectively-observational. The study included 50 patients of both 
genders, aged at least 65 years, who were treated in the first half 2012th in the 
Health Center Novi Sad which prescribed three or more drugs. Three sources of 
information about possible drug interactions were used: www.drugs.com, British 
National Formulary (BNF) and SPC of drug. RESULTS: The study included a total 
of 50 patients with mean age of 73.62 years. According to the number of possible 
drug interactions, most of them were from BNF (n = 204 or 45.43% compared to 
the number of possible drug combinations), then www.drugs.com (n = 203 or 
45.21%) and from SPC source were significantly less (n = 150 or 33.40%). In 
relation to the degree of relevancy of drug interactions, according to the source 
www.drugs.com, the incidence of serious interactions was 3%, 29% moderate 
and 13% mild. Out of 50 patients analyzed, only in 9 patients (18%) were found 
complete compatibility in the number of interactions in all three data sources. A 
significantly higher number of interactions were at the level of 
pharmacodynamic (167 or 77.68%). CONCLUSIONS: With the increasing number 
of taken drugs at the same time, increases the total number of interactions with 
a correlation coefficient of 0.71. Publications and Internet could provide useful 
information of drug interactions, but we could not say what else is important in 
a particular patient. This research was supported by Provincial Secretariat for 
Science and Technological Development, Autonomous Province of Vojvodina 
project No 114-451-2458/2011 and by Ministry of Science and Technological 
Development, Republic of Serbia project No 41012.  
 
PIH2  
DRUG INTERACTION LEAD MEDICATION ERRORS - EVIDENCE FROM AN INDIAN 
TERTIARY CARE SETTING  
Tiwari P1, Pipalava P2 
1National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. NAGAR, India, 
2NIPER, SAS NAGAR, India  
BACKGROUND: Medication errors is a major issue that every health care setting 
keeps addressing because it has a direct bearing on the safety of the patients. 
The results across the globe have demonstrated that the drug interactions 
continue to be a leading cause of errors. OBJECTIVES: The stduy was carried out 
with the obejctive of detecting the medication errors in the inpatients and profile 
them. METHODS: This study was carried out in an inpatient setting of a private 
tertiary care hospital. Medication errors were identified from patients' files, 
using Micromedex on PDA. 17 errors were fixed as the becnmark and 
assessments were done using this. RESULTS: The results are based on data 
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obtained from 1225 patients [709 male, 516 female]. The average age of the 
patients was found to be 56.8±0.5 years. The average number of medications 
prescribed was 10.6±0.2. 585 patients were found to be aged 60 years or more and 
613 patients were in the age group 18-60 years. Out of the 1225 patients, 848 did 
not have any medication error. An error was noted on only in 377 patient 
profiles. The total number of medication errors was found to be 638. Of these, 
597 were errors ‘with no harm’ and only 41 were errors ‘with harm’. Of these 
medication errors, drug interactions (DIs) were found to be leading the list with 
50% of the medication errors. Cardiovascular agents contributed maximum to 
the DIs followed by anticoagulants and antimicrobial agents. Only 172 DIs had a 
moderate severity. DIs was followed by duplication of therapy (20%), incorrect 
interval (10%), monitoring error, incompleteness of prescription, omission error 
and overdosing, respectively. CONCLUSIONS: These results confirm that drug 
interaction continue to lead the list of medication errors in Indian tertiary health 
care settings. The study is ongoing to determine the interventions to reduce the 
errors.  
 
PIH3  
DRUGS ASSOCIATED WITH ADVERSE DRUG EVENTS IN CHILDREN: ANALYSIS 
OF THE UNITED STATES FDA ADVERSE EVENT REPORTING SYSTEM DATABASE  
Lee WJ, Schumock GT, Lee TA 
University of Illinois at Chicago, Chicago, IL, USA  
OBJECTIVES: Compared to adults relatively little is known about drug safety in 
children. This study aims to describe the drugs and adverse events most 
commonly reported in the US spontaneous Adverse Event Reporting System 
(AERS) in children. METHODS: Adverse events reported to the US FDA AERS 
Database between 1 January 2007 and 30 June 2012 and occurring in children and 
adolescent (<18 years old) were examined. Demographic characteristics of the 
patients and reports were described by age, gender and reporter type. 
Additionally, the most commonly suspected drugs and the most frequently 
occurring adverse events in the AERS database were identified. RESULTS: We 
identified a total of 90,355 reports (average 16,428 reports/year) of primary 
suspect medications in children, of which 60.8% were for individuals < 12 years 
old and 50.6% were males. Physicians (30.5%) and consumers (27.4%) reported 
the majority of pediatric adverse drug events. Methylphenidate was the most 
frequently reported drug with 3,755 (4.2%) reports, followed by infliximab (3.0%) 
and isotretinoin (2.7%). Vomiting (1.3%), pyrexia (1.2%), convulsion (1.1%), drug 
ineffective (1.0%) and product quality issue (0.9%) were the top five reported 
adverse events. However, dyspnoea and pneumonia became the fourth and fifth 
leading adverse events respectively when restricting our analysis to only severe 
events (i.e., resulting in hospitalization, life-threatening events, or death). 
CONCLUSIONS: Data from post-marketing surveillance of adverse events can 
add to our understanding of drug safety in children. A large proportion of events 
reported to the FDA are not considered severe and focusing solely on severe 
events is likely important to identify potential high risk medications. Subsequent 
analyses of the most commonly reported drug causes of severe adverse events 
may lead to important safety questions.  
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A PILOT STUDY OF PHARMACOTHERAPY (NALTREXONE) FOR HAZARDOUS 
DRINKING AMONG WOMEN INFECTED WITH HIV  
Hu X1, Weber K2, Karki M1, Cohen M3, Young M4, Thoma K5, Thomas G5, Rathore M5,  
Mai D4, Cook R1 
1University of Florida, Gainesville, FL, USA, 2Stroger Hospital, Chicago, IL, USA, 3Stroger Hospital 
and Rush University, Chicago, IL, USA, 4Georgetown University Medical Center, Washington, DC, 
DC, USA, 5University of Florida, Jacksonville, FL, USA  
OBJECTIVES: Pharmacological treatment is effective in reducing hazardous 
drinking in persons with alcohol dependence, while little is known whether it is 
effective in HIV patients. The purpose of this study was to examine feasibility 
and effectiveness of using pharmacotherapy (naltrexone) on women infected 
with HIV. METHODS: The NIAAA-sponsored pilot study was a double-blind, 
randomized controlled trial. Women with HIV who met criteria for NIAAA-
defined past-year hazardous drinking were recruited from HIV clinical settings in 
Jacksonville (FL) and the Women’s Interagency HIV Study (WIHS) in Chicago (IL) 
and Washington DC. Participants were randomized 2:1 to oral naltrexone (50mg) 
or placebo for 4 months; outcomes were assessed 2, 4 and 7 months after 
enrollment. RESULTS: From December, 2010 to February, 2012, 19 women were 
enrolled (mean age 48.8 years, 95% African American). Approximately 70% of 
eligible women were successfully enrolled at two WIHS sites, compared with 12% 
at the clinical site in Jacksonville (FL). Almost all women reported prior use of 
other drugs (heroin, 3; methadone, 3; cocaine, 13; marijuana, 14; tobacco, 16). 
Among 14 (74%) women who completed the study, average daily alcohol 
consumption dropped significantly from 7.13 standard drinking units (SDUs) at 
baseline to 0.46 SDUs at month 7. CONCLUSIONS: Although the sample is small, 
this pilot study demonstrates the feasibility of conducting a larger study to 
determine the impact of naltrexone on alcohol consumption and health 
outcomes in women with HIV. Although enrollment of HIV-infected women into 
alcohol treatment trials can be challenging, we demonstrated that these 
challenges can be minimized by recruiting from previously established long term 
cohorts that directly address alcohol consumption. Health outcome, especially 
alcohol consumption reduction, reported in this study will provide valuable 
input for future decision analytical models to evaluate the cost-effectiveness of 
using pharmacotherapy treating hazardous drinking among HIV patients.  
 
PIH5  
EFFECT OF ASCORBIC ACID ON BLOOD LEAD LEVELS AMONG SCHOOL GOING 
ADOLESCENTS IN KARACHI: A CLUSTER RANDOMIZED TRIAL  
Gilani AH1, Ilyas M2, Nuruddin R2, Islam M3 
1Department of Biological and Biomedical Sciences, The Aga Khan University, Karachi, Pakistan, 
2The Aga Khan University, Karachi Pakistan, Karachi, Pakistan, 3The Aga Khan University, 
Karachi Pakistan, Karachi, PR  
OBJECTIVES: There is no safe range for Blood Lead Levels (BLL) in humans. Lead 
is associated with many adverse health outcomes in children because of more 
susceptibility to environmental lead. We aimed to explore a convenient and cost-
effective strategy for decreasing BLL among adolescent with the objective to 
assess the effect of Ascorbic-acid on BLL among school going adolescent of 
Karachi. METHODS: A cluster randomized trial was conducted in schools, 
randomized to 250mg or 500mg of Ascorbic-acid (four clusters each). BLL was 
measured at baseline and after four weeks of intervention. Lead exposure was 
assessed through a questionnaire at baseline and dietary Vitamin-C through 
Food Frequency Questionnaire (FFQ) at follow-up. The cluster adjusted difference 
between the groups calculated through independent t-test and within group 
difference through paired t-test. A multiple-linear-regression model was built for 
adjusting residual confounders. RESULTS: A total 144 individuals were recruited. 
The overall mean BLL at baseline was 12.9mg/dl (95%CI; 12.2-13.8). For Ascorbic-
acid 250mg and 500mg it was 13.4mg/dl (95%CI; 12.1-14.7) and 12.5mg/dl (95%CI; 
11.7-13.4) respectively. The mean decline in BLL was 2.7mg/dl (p=0.002) and 
3.29mg/dl (p<0.001) in 250mg and 500mg respectively. The mean difference in 
BLL decline between two group was 0.6mg/dl (p=0.824). On an average, for one 
mg/dl increase in baseline BLL, the decreased was 0.8mg/dl after adjusting for 
chipping-off of school paint and intervention group (p<0.001). CONCLUSIONS: 
The overall mean baseline BLL of our sampled population was above  
the acceptable level recommended by CDC (10mg/dl). Oral supplementation  
of Ascorbic-acid in both 250mg & 500mg significantly decreased BLL. However, 
the dose dependent decline was statistically insignificant. In adolescent who  
had initially elevated BLL showed greater decline at follow-up. Thus, using 
Ascorbic-acid 250mg or 500mg daily could be a cheap, safe and easily available 
strategy to lower BLL among adolescent particularly those living in highly 
exposed areas.  
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DRUG USE EVALUATION AT AN INDIAN PUBLIC TEACHING HOSPITAL  
Tiwari P1, Kumar A2, Sachdev A3, D'cruz S3 
1National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. NAGAR, India, 
2NIPER, SAS NAGAR, India, 3Govt Med Coll Hosp, Chandigarh, India  
OBJECTIVES: To evaluate prescribing pattern in an inpatient setting of a public 
teaching hospital in India. METHODS: Patient records were collected from 
general medicine wards of a public teaching hospital over a period of 7 months. 
The data were analyzed using WHO recommended prescribing indicators: The 
National List of Essential Medicines-2003 of India (NLEM-2003) was used to 
analyze prescribing from essential drug list. The results were presented as 
average±SEM, median (inter quartile range) and percentages, as applicable. 
RESULTS: A total of 710 inpatients’ records were analyzed. Over two thirds of 
patients (67.6%) had only one diagnosis and the average number of diagnosis 
was 1.4±0.02. The average number of medicines prescribed was found to be 7.3. 
The percentage of medications prescribed from NLEM was 65%. Approximately 
14.6% medications were prescribed by generic names. The percentage of 
prescriptions with an injection(s) and antibiotic(s) were 85.9% and 68.6%, 
respectively. CONCLUSIONS: This study has provided real-time evidence that the 
prescribers in public teaching hospital were aware of the NLEM-2003. There are 
areas, in addition to this, which require consolidation to promote rational drug 
therapy.  
 
PIH7  
THE PREVALENCE, INCIDENCE, AND TREATMENT RATES OF HYPOGONADISM 
IN MEN ACROSS GEOGRAPHIES: A SYSTEMATIC LITERATURE REVIEW  
Huang MY1, Parker G2, Zarotsky V2, Carman W3, Morgentaler A4, Jones H5, Singhal P6 
1Temple University, West Point, PA, USA, 2Optum, Eden Prairie, MN, USA, 3Optum, Ann Arbor, 
MI, USA, 4Men's Health Boston, Boston, MA, USA, 5Robert Hague Centre for Diabetes and 
Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, UK, 6Merck & Co., Inc, West 
Point, PA, USA  
OBJECTIVES: To conduct a systematic literature review to assess the prevalence, 
incidence, and treatment rates of hypogonadism in men across geographies. 
METHODS: The literature search was undertaken within the PubMed/MEDLINE, 
Embase, and Cochrane databases for articles published between 1992 and 2012. 
Articles were excluded from this review if the sample size was less than 30. 
RESULTS: We reviewed 175 citations/abstracts and identified 109 relevant 
articles. Numerous cut-off points for testosterone level were used to define 
hypogonadism; however, the most widely used definitions were total 
testosterone <300 ng/dL (10.41nmol/L) and free testosterone <5ng/dL 
(<0.174nmol/L). Few studies used the combination of symptoms and testosterone 
level cut-off points to define hypogonadism. The prevalence, incidence, and 
treatment rates of hypogonadism across studies varied widely depending upon 
the population studied and how hypogonadism was defined. The overall 
prevalence rates for hypogonadism based on population-based studies were: US, 
3.8% - 20.4%; Chile, 28.1%; Germany, 3.4% - 5%; Finland, 19.8%; Malaysia, 6.0% - 
16.1%; Taiwan, 12.0% and Hong Kong, 9.5%. Prevalence also increased with age 
and in the presence of co-morbid conditions. The incidence per 1000 person-
years was 12.3 in the US and 11.7 in Germany. Treatment rates varied 
dramatically in different studies and populations and were generally very low 
(9.6% - 11.3% of men with hypogonadism). CONCLUSIONS: The literature review 
suggested that there is potentially a significant burden of hypogonadism in the 
general population. Burden seems to increase with age and in the presence of 
certain disease conditions. Inconsistent disease definitions and diagnostic 
